Preview

Пульмонология

Расширенный поиск

Параметры фармакокинетики современных ингаляционных глюкокортикостероидов

Полный текст:

Об авторе

А. Н. Цой
Московская медицинская академия им.И .М .Сеченова
Россия


Список литературы

1. Бронхиальная астма. Глобальная стратегия. Основные направления лечения и профилактики астмы: Совместный доклад Национального института сердце, легкие, кровь и Всемирной организации здравоохранения. Русская версия под общ. ред. акад. А.Г.Чучалина / / Пульмонология.— 1996.— Прилож.— С.1 — 157.

2. Barnes N.C. Advances in inhaled steroid therapy / / Eur. Respir. Rev.— 1994.— Vol.4, № 21,— P.295—300.

3. Barnes P.J. Inhaled glucocorticoids: new developments relevant to updating the asthma management guidelines / / Respir. Med.— 1990.— Vol.9.— P.379—384.

4. Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids / / Amer. J. Respir. Crit. Care Med.— 1998.— Vol.157.— P.S51—S53.

5. Barry P.W., Callaghan C.O. Inhalation drug delivery from seven different spacer devices / / Thorax.— 1996.— Vol.51.— P.835—840.

6. Billheimer J.T., Gillies P.J. Intracellular cholesterol esterification / / Advances in Cholesterol Research / / Eds M.Esfahani, J.B.Swaney.— New York: The Telford Press, 1990.— P.7—145.

7. Borgstrorn L.E., Derom E., Stahl E. et al. The inhalation device influences lung deposition and bronchodilating effect of terbutaline / / Amer. J. Respir. Crit. Care Med.— 1996.— Vol. 153.— P. 1636—1640.

8. Brattsand R., Axelsson B. New inhaled glucocorticosteroids / / New Drugs for Asthma / Ed. P.J.Barnes.— London, 1992.— Vol.2.— P. 193—208.

9. Brattsand R. What factors determine antiinflammatory activity and selectivity of inhaled steroids / / Eur. Respir. Rev.— 1997.— Vol.7.— P.356—361.

10. British Thoracic Society. The British guidelines on asthma management / / Thorax.— 1997.— Vol.52.— S uppl.l.— P .S1—S21.

11. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety / / Respir. M ed.— 1997.— Vol.91.— Suppl.A.— P.22—28.

12. Esmailpour N., Hogger P., Rabe K.F. et al. Distribution of inhaled fluticason propionate between human lung tissue and serum in viv o / / Eur. Respir. J.— 1997.— V o l.10.— P. 1496—1499.

13. Falcoz C., Kirby S.M., Smith J. et a l. Pharmacokinetic and systemic exposure of inhaled beclomethasone dipropionate (abstract) / / Ibid.— 1996.— Vol.9.— Suppl.23.— P.162s.

14. Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report № 2. National Institutes of Health, Bethesda, MD. (N IP Publication № 97— 4051).— Bethesda, 1997.

15. Hogger P., Ravert J., Rohdewald P. Dissolution, tissue binding and kinetics of receptor binding of inhaled glucocorticoids / / Eur. Respir. J.— 1993.— Vol.6, Suppl.17.— P.584s.

16. Hogger P., Rohdewald P. Binding kinetics of fluticason propionate to the human glucocorticoid receptor / / Steroids.— 1994.— Vol.59.— P.597—602.

17. Hogger P., Erpenstein U., Sorg C. et al. Receptor affinity, protein expression and clinical efficacy of inhaled glucocorticoids / / Amer. J. Respir. Crit. Care M ed.— 1996.— Vol. 153.— № A336.

18. Jackson W.F. Nebulised budesonid therapy / / Asthma: Scientific and Practical Review.— Oxford, 1995.— P.l—64.

19. Jenner W.N., Kirkham D.J. Immunoassay of beclomethasone 17, 21-dipropionate and metabolites / / Bioanalysis of Drugs and Metabolites / Eds E.Reid et al.— New York, 1988.— P.77—86.

20. Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids / / J. Allergy, clin. Immunol.— 1996.— Vol.97.— P.169—176.

21. Kenyon C.J., Thorsson L., Borgstrorn L. Reduction in lung deposition of budesonide pressurized aerosol resulting from static change? In plastic spacer devices / / Drug Delivery Lungs.— 1996.— Vol.7.— P.17—18.

22. McKenzie A.W., Stroughton R.B. Method for comparing percutaneous absorbtion of steroids / / Arch. Derm.— 1962.— Vol.86.— P.608—610.

23. Miller-Larsson A., Maltson R.H., Ohlsson D. et al. Prolonged release from the airway tissue of glucocorticods budesonile and fluticasone propionate as compared to beclomethasone dipropionate and hydrocortisone (abstract) / / Amer. J. Respir. Crit. Care Med.— 1994.— Vol.149.— № A466.

24. Miller-Larsson A., Jansson P., Runstrom A. et al. Reversible fatty acid conjugation of budesonide results in a prolonged topical anti-inflammatory activity in airways as compared to fluticasone propionate (abstract) / / Ibid.— 1997.— Vol. 155.— № A353.

25. Miller-Larsson A., Maltson R.H., Hjertberg E. et al. Reversible fatty acid conjugation of budesonide: novel mechanism for prolonged retention of topically applied steroid in airway tissue / / Drug Metab. Dispos.— 1998.— Vol.26, № 7.— P.623—630.

26. Pedersen S., Byrne P.O. A comparison of the efficacy and safety of inhaled corticosteroids in asthma / / Eur. J. Allergy clin. Immunol.— 1997.— Vol.52.— Suppl.39.— P .l—34.

27. Selroos O., Pietinalho A., Lofroos A.B., Riska A. High-dose is more effective than low-dose inhaled corticosteroids when starting medication in patients with moderately severe asthma (abstract) / / Amer. J. Respir. Crit. Care M ed.— 1997.— Vol. 155.— № A349.

28. Thorsson L., Edsbacker S., Conradson T.B. Lung deposition of budesonide from Turbuhaler is twice that from a pressured metered-dose-ingaler p-MDI / / Eur. Respir. J.— 1994.— Vol.7.— P.1839—1844.

29. Thorsson L., Kallen A., Wiren J.E., Paulson J. Pharmacokinetics of inhaled fluticason propionate (abstract) / / Ibid.— 1996.— Vol.9.— Suppl.23.— P.164s.

30. Thorsson L., Dahlstrom K., Edsbacker S. et al. Pharmacokinetics and systemic.effects of inhaled fluticasone propionate in healthy subjects / / Br. J. clin. Pharmacol.— 1997.— Vol.43.— P.155—161.

31. Todd G., Danlop K., Carson D., Shields M. Adrenal suppression in asthmatic children treated with high-dose fluticason propionate $ (abstract) / / Amer. J. Respir. Crit. Care Med.— 1997.— Vol. 155, № 4, Pt 2.— № A356.

32. Trescoli-Serrano C., Ward W.J., Garcia-Zarco M. et al. Gastroinstestinal absorbtion of inhaled budesonide and beclomethasone: has it any significant systemic effect? / / Ibid.— 1995.— Vol.151, № 4, Pt 2.— № A375.

33. Tunec A., Sjodin K., Iiallstrom G. Reversible formation of fatty acid esters of budesonide, an anti-asthma glucocorticoid, in human lung and liver microsomes / / Drug Metab. Dispos.— 1997.— Vol.25.— P.1311 — 1317.

34. Van den Bosch J.M., Westermann C.J.J., Edsbacker J. et al. Relationship between lung tissue and blood plasma concentrations of inhaled budesonide / / Biopharm. Drug Dispos.— 1993.— Vol.14.— P.455—459.

35. Wieslander E., Delander E.L., Jarkelid L. et al. Pharmacological importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line in vitro / / Amer. J. Respir. Cell. Mol. Biol.— 1998.— Vol.19.— P .l—9.

36. Wurthwein G., Render S., Rodhewald P. Lipophility and receptor affinity of glucocorticoids / / Pharm. Ztg, Wiss.— 1992 — Bd 137.— S.161 — 167.


Для цитирования:


Цой А.Н. Параметры фармакокинетики современных ингаляционных глюкокортикостероидов. Пульмонология. 1999;(2):73-79.

For citation:


Tsoy A.N. Pharmacokinetik parameters of modern inhaled glucocorticoids. PULMONOLOGIYA. 1999;(2):73-79. (In Russ.)

Просмотров: 4


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)